The range of uncertainty: A tool for efficiently addressing result variability around clinical decision points for hepatitis c response-guided therapy

Biomarker Insights

Volumn 9, Issue , 2014, Pages 9-13

  Jülicher, Paul ^a   Dhein, Jens ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Hepatitis C; In vitro diagnostic tests; Precision; Response guided therapy; Standardization; Viral load

Indexed keywords

VIRUS RNA;

ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEPATITIS C; REFERENCE VALUE; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UNCERTAINTY; VIRUS LOAD;

EID: 84898447159     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s14481     Document Type: Article

References (16)

1. Reitsma JB, Rutjes AWS, Khan KS, Coomarasamy A, Bossuyt PM. A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol. 2009;62(8):797-806.
2. Holden MJ, Madej RM, Minor P, Kalman LV. Molecular diagnostics: harmonization through reference materials, documentary standards and proficiency testing. Expert Rev Mol Diagn. 2011;11(7):741-55.
3. Panteghini M. Traceability as a unique tool to improve standardization in laboratory medicine. Clin Biochem. 2009;42(4-5):236-40.
4. Pauker SG, Kassirer JP. Therapeutic decision making: a cost-benefit analysis. N Engl J Med. 1975;293(5):229-34.
5. Yee HS, Chang MF, Pocha C, et al. Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107(5):669-89.
6. Wedemeyer, H. On the fast track towards IFN-free therapy for hepatitis C? Nat Rev Gastroenterol Hepatol. 2013;10(2):76-8.
7. Jacobson IM, Marcellin P, Zeuzem S, et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology. 2012;56(2):567-75.
8. Pisani G, Cristiano K, Marino F, et al. Quantification of hepatitis C virus (HCV) RNA in a multicenter study: implications for management of HCV genotype 1-infected patients. J Clin Microbiol. 2009;47(9):2931-6.
9. de Leuw P, Sarrazin C, Zeuzem C. How to use virological tools for the optimal management of chronic hepatitis C. Liver Int. 2011;31 Suppl 1:3-12.
10. Wedemeyer H, Kessler HH, Michel-Treil V, et al. The ExPECT Study: an international multicenter clinical trial evaluating low HCV RNA viremia with the COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 compared to assays used in routine clinical practice and drug trials. Poster presented at: AASLD Meeting, November 9-13, 2012; Boston, MA.
11. Braun P, Naeth G, Berger A, et al. Comparison of viral load assays for the quantification of HCV genotype 1 in the setting of low viremic samples. Poster presented at: CROI 2013; Atlanta, GA.
12. Maasoumy B, Cobb B, Bremer B, et al. A clinical trial evaluating low HCV RNA viremia in patients treated with triple therapy including Telaprevir: implications for management using different assays in clinical practice. Poster presented at: EASL Meeting 2013; April 24-28, 2013; Amsterdam, the Netherlands.
13. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for treatment of chronic hepatitis C. a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279-90.
14. Dekking FM, Kraaikamp C, Lopuhaä HP, Meester LE. A modern introduction to probability and statistics. London: Springer; 2010.
15. Wachtel TJ, Reuben DB, Fulton JP, Wartman SA. The use of the "range of uncertainty". Med Decis Making. 1985;5(3):325-34.
16. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012;344:e686.